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CHAPTER 1: INTRODUCTION 
Obesity is increasing at an alarming proportion in most developed 
countries and also in countries adopting a Western lifestyle. In fact, obesity is now 
considered a global epidemic.l In the United States alone, approximately 60°Io of adults are 
overweight (body mass index > 25.0-29.9 kg/m2) or obese (BMI > 30 kg/m2). 2 The concern 
regarding this prevalence is that obesity is associated with several adverse health 
consequences including cardiovascular, metabolic, mental, and orthopedic diseases. 3, 4 
Obesity and its co-morbidities (e.g., cardiovascular disease [CVD], type 2 diabetes, 
etc.) are not limited to adults. Recent epidemiological data from the 1999-2000 National 
Health and Nutrition Examination Survey (NHANES) shows that approximately 15°Io of 12-
19 year old adolescents in the United States are considered obese (body mass index > 95th
percentile of age- and sex-specific reference values) which is a 5 °Io increase since NHANES 
III (1988-1994) and an almost 3-fold increase since the first national survey of 1966-1970. s 6 
Childhood obesity is also associated with medical consequences as children are experiencing 
an earlier development of complications related to obesity. Specifically, obese adolescents 
are at an increased risk for the metabolic syndrome, which is a clustering of dyslipidemia, 
hypertension, and a disturbance in glucose metabolism ~ 
Recent findings in adipocyte biology have shown that the adipocyte not only stores 
triglycerides but is also a hormonal secretory organ. In the past ten years, many new. 
hormones/cytokines such as leptin, interleuken-6 (IL-6), resistin, tumor necrosis factor-alpha 
(TNF-a), and adiponectin have been identified as originating in adipose tissue .g Collectively, 
these secretory products of adipocytes can be referred to as adipocytokines. Of these 
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adipocytokines, adiponectin is the most abundant of all the adipocyte-released hormones. 
Adiponectin has been shown to influence insulin sensitivity and anti-inflamatory/anti- 
atherogenic reactions.9' 1 ° Since insulin resistance and atherogenisis are major contributors to 
CVD, the control of these conditions are crucial in maintaining cardiovascular and metabolic 
health. 
Despite a growing literature on adipocytokines, there has been limited research on 
adiponectin and adolescents. A recent MEDLINE search revealed only 50 papers using the 
key terms "adiponectin and adolescents". The majority of these papers focused on the 
relationship between adiposity and adiponectin, and more specifically, adiponectin in obese 
adolescents. In general, this research has shown that adiponectin levels are inversely 
associated with adiposity, l 1, 12 and that adiponectin increases following weight loss in obese 
adolescents.12 The lower adiponectin concentration associated with an increased fatness may 
play a role in the pathogenesis of obesity and the metabolic syndrome.11
Physical activity has been shown as an important factor regulating the growth and 
maturation of the fat depot. Research has shown that increasing physical activity and a 
reduction of caloric intake can result in a decrease of adipose tissue. ' 3 Increasing physical 
activity alone can also decrease the fat depot. Although there is research supporting physical 
activity as a mediator of weight loss and thus a method for preventing the development of 
obesity, there is a lack of research investigating the independent effects of physical activity 
on the inflamed state that develops with excess adiposity. Currently, there are no published 
studies that determine the relationship between physical activity and adiponectin levels in 
adolescents. Therefore, the purpose of this thesis is to examine the inter-relationships among 
physical activity, body fatness and adiponectin in adolescent males. 
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Significance of the study 
Current research on adiponectin has focused on the physiological interactions 
between adiponectin and various metabolic processes within the body. 14-16 In general, 
adiponectin has shown adverse effects on CVD risk factors.16' 17 It can also be inferred from 
the research that higher circulating concentrations of adiponectin are important for the 
prevention of the metabolic syndrome and CVD. 16, 17 However, there is a need for research 
focusing on clinical applications, especially in the adolescent population. The various 
clinical studies conducted on adolescents focus on weight/adiposity relationships with 
adiponectin concentrations.12 Research in the adolescent population has neglected to 
investigate the possible relationship between physical activity and adiponectin 
concentrations. Physical activity may benefit adolescents by increasing adiponectin 
concentrations and thus the identification of a possible relationship between physical activity 
and adiponectin levels could lead to physical activity recommendations to maintain proper 
health in adolescents. 
Limitations 
Since androgens are not being measured in this study, the influence androgens have 
on adiponectin levels in adolescents may be a potential limitation. To control for androgen 
involvement, the study will use male participants between the age of 12 and 18 years. In 
order to control for variation in age, maturity status will be assessed and statistically 
controlled. Due to the influence of adiposity on adiponectin concentrations, adiposity will 
also be controlled in the analysis. Another area where a limitation exists is in physical 
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activity assessment. Currently there is not a "gold standard" measurement for physical 
activity; every method has its strengths and weaknesses. 
Research Hypotheses 
Young males with higher levels of regular physical activity will have increased 
plasma adiponectin concentrations independent of age and adiposity. 
Thesis Organisation 
This thesis is structured into four key sections. The first of which is a general 
introduction which briefly identifies background information on the subject and identifies the 
purpose of the study. Following the introduction is comprehensive literature review that 
examines the current literature on the subject at hand, building the case for the relevance of 
the study. Section three is the complete study in manuscript form that is intended for 
publication. The fourth and last section summarizes the main conclusions. All works cited 
are in the format required by the Journal of American Medical Association. 
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CHAPTER 2: REVIEW OF LITERATURE 
Introduction 
The epidemic of obesity in children and adults continues to stimulate research into 
the causes and complications related to the disease. Recent findings on the function of 
adipose tissue as a secratory cell has shifted research into a new direction. The discovery of 
hormonal secretions from adipose tissue changes the original and long-standing view of fat 
being a storage depot. 1 These adipose secreted hormones, known as adipocytokines, have 
profound and wide spread physiological effects on the body. One such adipocytokine is 
adiponectin, which has been shown to influence insulin sensitivity and the development of 
atherosclerosis. The purpose of this review of literature is to address the epidemiology of 
pediatric obesity, the complications of childhood obesity, and adiponectin. 
Epidemiology of Pediatric Obesity: Prelavance and Consequences 
In the past few decades, there has been a substantial increase in childhood and 
adolescent obesity in several nations of the World. In the United States over 15 % of the 
youth are obese.2 Along with the increase in obesity, children are developing complications 
that normally occur in adults, such as type II diabetes and the metabolic syndrome. 3 Excess 
weight in childhood can also lead to greater complications in adulthood. An increased BMI 
can track from childhood into adulthood. 4 In order to test whether BMI tracked into 
adulthood Srinvasan et a1.4 analyzed the Bogalusa Heart Study data, children in the highest 
BMI and insulin levels were at greater risk for developing adult complications (odds ratio of 
11.7 and 3.6 respectively). Between the two aforementioned predictors, BMI had the 
strongest relationship to a clustering of metabolic complications later in life.4 Similar 
research has identified that an increase in adiposity during childhood can be a predictor of 
cardiovascular risk factors. Freedman et a1.5 investigated the relationship between 
overweight participant classification and cardiovascular risk factors in children using the 
Bogalusa Heart Study data. Freedman's group found that 20% of overweight children have 
one CVD risk factor, with 80% of that 20% having three or more risk factors. The most 
common risk factors in overweight children are high triglycerides and low concentrations of 
high density lipoprotein cholesterol (HDLG). 5
The Adipocyte: Beyond a Storage Depot 
Traditionally, adipose tissue has been considered to function as a storage depot for 
triglycerides and insulation for retention of body temperature. However, recent research has 
found that adipose tissue is not only used for triglyceride storage, but also has hormonal 
functions. The discovery of lipoprotein lipase, a protein structure that is released from 
adipose tissue, in the mid 1980's provided the first evidence that adipose tissue is more than 
just a storage depot. 6 In 1994, roughly ten years after the identification of lipoprotein lipase, 
Zhang et al. l discovered leptin a cytokine released from adipose tissue, thus identifying 
adipose tissue as a hormonal organ.l The cytokine leptin was later shown to be involved in 
energy homeostasis. ~ Shortly after leptin was identified other adipocytokines (cytokines 
originating from adipose tissue) that have diverse effects on whole body physiology where 
discovered. To date, more than 10 adipocytokines have been identified. (See Table 1 on next 
page)$ With the advancement of technology new adipose derived biomarkers are continuing 
to be discovered. ' 1 One such adipocytokine is adiponectin, which has been shown to have 
anti-inflammatory and insulin sensitizing properties.9, l o 
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Table 1. Listing of common adipocytokines and their function 
General Biology of Adiponectin 
Adipocytokine Major Function 
Leptin Energy homeostasis 
Tumor Necrosis Factor Alpha (TNF- a) Inflammatory response, insulin 
resistance 
Interleuken-6 (IL-6) Energy homeostasis 
Macrophages and Monocyte Chemoattractant 
Protein (MCP-1) 
Inflammatory response, monocyte 
accumulation 
Plasminogen Activator Inhibitor (PAI-1) Inhibits fibrinolysis, angiogenesis, 
atherogenisis 
Adiponectin Anti-inflammatory, Anti-
atherogenic, Insulin Sensitivity 
Adipsin and Acylation Stimulating Protein (ASP) Influences lipid and glucose 
metabolism 
Resistin Insulin resistance 
Angiotesin Family (AT1,AT2, ACE) Electrolyte balance, vascular tone 
Visfatin Insulin Sensitivity 
Adiponectin is a 244 amino acid residue that is exclusively produced in 
white adipose tissue with a similar structure to tumor necrosis factor alpha.12 The gene for 
human adiponectin expression is on chromosome 3g27. '3 Adiponectin was originally named 
APM1 (adipose most abundant gene transcript) because it is the most abundantly transcribed 
gene in adipose tissue. 12 Adiponectin makes up approximately 0.01% of total plasma content 
in healthy individuals, 14 which is almost 1,000 times greater than the remaining adipocyte 
released (adipocytokine) hormones. 15 
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Adiponectin differs from other adipocytokines because it decreases as adiposity 
increases, which is the opposite reaction from the rest of the known adipocytokines. 
Adiponectin has been shown to be inversely correlated to FFA concentrations and 
triglycerides; and positively related to HDL cholesterol, thus it has been related to obesity 
and the metabolic syndrome.16
Adiponectin and the Metabolic Syndrome 
Adiponectin is linked to influencing contributors of the metabolic syndrome. 
The metabolic syndrome consists of the co-occurrence of visceral obesity, dyslipidemia, 
insulin resistance, and hypertension.l ~ Increased adiposity and physical inactivity are also 
related to the metabolic syndrome. As a result of increased adiposity and physical inactivity, 
the metabolic syndrome is more common in people that are considered to be overweight or 
obese. Effects of the metabolic syndrome can lead to a greater risk of developing 
cardiovascular complications such as atherosclerosis.'s Amain contributor to the 
complications associated with the metabolic syndrome is insulin resistance. 
Insulin resistance is when the body becomes desensitized to insulin causing less 
glucose to enter the cells. When glucose cannot enter the cells for metabolism, alternate fuel 
sources are needed. The main fuel source that is relied upon when glucose metabolism 
cannot be used is fat. However, the problem with relying on fat for energy is that there is a 
greater amount of free fatty acids (FFA) in the blood. In turn these free fatty acids can attach 
to damaged areas in the endothelium and cause atherosclerosis. 
Adiponectin has been found to decrease the level of insulin resistance. ' 9 
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In obese mice the administration of adiponectin lowers plasma glucose concentrations and 
prevents plasma triglyceride increase while lowering liver and muscle triglyceride content. 20
Yamauchi et a1.21uncovered similar findings in mice with adiponectin injection, their data 
supports the findings that adiponectin increases r'r'A utilization (adiponectin increases Beta-
oxidative enzymes) thus reducing stored triglyceride content in the muscle and liver. It is 
believed that excess triglycerides in tissue can hinder glucose transport and subsequent 
uptake. Yamauchi and colleagues concluded that insulin sensitivity is increased via a 
lowering of triglycerides. 21 
Another area related to insulin sensitivity is glucose production. Endogenous 
glucose production has been negatively correlated to adiponectin. A decrease in endogenous 
glucose production in turn lowers the need for increased insulin secretion. Lowered glucose 
production via increased adiponectin concentrations may have a hindering effect on the 
development of type II diabetes or the metabolic syndrome. 22, 23 
Adiponectin and Atherosclerosis 
Along with the insulin sensitizing properties of adiponectin, it also has anti- 
atherogenic effects on vascular tissue. Atherosclerosis is the main cardiovascular 
complication within cardiovascular disease, which is the leading causes of death in several 
developed countries.'$ Each year approximately 38% of all deaths in the United States per 
year are caused by cardiovascular disease.24 Atherosclerosis is the deposition of body 
materials (mostly lipids and monocytes) in the vascular tissue where an injury has occurred. 
The main cause of atherogenesis is the development of crystallized plaque on the 
endothelium.25 This plaque is the result of increased monocyte binding with endothelial 
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tissue. Monocyte binding influences the uptake of low density lipoproteins. Low density 
lipoproteins are taken up to form foam cells which turn into atherosclerotic plaque. The 
uptake of low density lipoproteins are modulated through scavenger A macrophage 
receptors.26, 27 The previously mentioned Atherosclerotic processes have been identified as 
starting in children.5
Adiponectin has been shown to decrease the formation of atherosclerotic plaques by 
30% in mice.28 A decrease in atherosclerotic formation with adiponectin may be related to 
adiponectin's inhibitory effect on foam cell formation through hindering class A 
scavengers.29 Adiponectin has been found in areas of injured endothelium where 
populations of macrophages are present. 29 Adiponectin is not detected in areas where 
endothelium remains whole, suggesting adiponectin presence at injured endothelial tissue is 
part of an anti-inflammatory response. Ouchi et al. 29 established that the treatment of 
adiponectin administered over 3 days decreases cholesterol ester in macrophages by 50%. 
Adiponectin is not only effective in slowing down the process of atherogenesis but 
it may also have an inhibitory role in the early phases of atherosclerotic development. When 
an injury first occurs to the endothelium an inflammatory response is initiated. This 
inflammatory response leads to an increased adhesion of monocytes to the endothelial tissue. 
One inflammatory marker that is present during the initial phase of injury is tumor necrosis 
factor alpha (TNF-a). TNF-a is directly associated with an increase in monocyte adhesion. 
Once TNF-a binds to its prospective site it initiates a cascade of reactions that result in 
monocyte adhesion ~0 Research has shown that adiponectin interferes with atherosclerosis by 
preventing monocyte binding to endothelial tissue. However, adiponectin's inhibition of 
monocyte binding does not occur via the hindering of TNF-a binding, rather it acts through 
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the disruption of TNF-a signaling after it has bound to the cell. This disruption in TNF-a 
signaling prevents activation of NF-kB which is a controller of monocyte adhesion and 
inflammatory response. Decreased monocyte binding leads to a smaller uptake of low density 
lipoprotein, causing smaller development of atherosclerotic plaque.l o 
If an atherosclerotic situation is not interrupted by adiponectin and has damaged the 
vascular structure substantially enough to cause ischemic conditions, adiponectin can still 
intervene. Shibata et a1 31 concluded that adiponectin has angiogenic properties in vivo in 
mice. After an ischemic condition was indicated in the mice an 80°Io recovery to normal 
blood flow levels occurred in the adiponectin producing mice compared to adiponectin 
deficient mice.31 Angiogenesis is an important mediator in keeping normal blood flow, 
preventing cardiac episodes. 
Sex-associated Variation in Adiponectin 
Adiponectin levels differ between males and females even after BMI and/or body 
fat is statistically controlled.19 With women having greater concentrations of adiponectin 
compared to their male counterparts. Research comparing men and women with the same 
BMI shows women having larger concentrations of adiponectin even with greater amounts of 
19, 32, 33 adipose tissue. 
Gender differences in adiponectin have been investigated in a mouse model using 
castrated mice that received androgen replacement. 32 Androgens such as testosterone were 
found to decrease adiponectin concentrations in the mouse model. From animal research it 
can be inferred that gender differences in humans may be related to the higher androgen 
levels in males.32 The gender paradigm seen in adults is also present in the youth; boys have 
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lower adiponectin concentrations compared to girls. Research has shown that the gender 
differences are not present in pre-pubescent. Prior to the initiation of puberty, boys and girls 
have similar levels of adiponectin; children also have higher adiponectin concentrations 
compared to the adult population. Research in adiponectin during puberty has shown that 
adiponectin concentrations are inversely related to development. (See Graph 1)34 At the 
beginning of puberty, boys experience a decline in adiponectin levels followed with an 
inverse relationship of adiponectin and stage of puberty. The age-pubertal changes seen in 
boys have not been shown to be present in girls. Thus, gender differences in adolescents may 
also be related to androgen release, which is similar to the adult population.33
Figure 1. Adiponectin concentrations with increasing age 
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Adiponectin in obese and non-obese adolescents 
The majority of adiponectin research involving adolescents has investigated the 
differences between obese and non-obese individuals. In addition, studies have also 
addressed the affects of weight loss. In general, results in adolescents are similar to what is 
seen in the adult population. Adiponectin concentrations in adolescents are negatively 
correlated to adiposity. More specifically, the amount of visceral adiposity influences 
adiponectin levels. The higher visceral fat(non-obese: 39 cm ,obese 71 cm2), the lower the 
adiponectin concentrations( 14 ~,g/ml and 9.2 ~,g/ml).35 Accompanying the lower 
adiponectin levels in obese adolescents, there is an increase in insulin concentrations due to 
the lowering of insulin sensitivity.3s 36 Adiponectin is positively correlated with insulin 
sensitivity in adolescents even after accounting for BMI and sex differences. 37' 3g With 
increased insulin concentrations, there are more triglycerides and free fatty acids present in 
overweight adolescents. 3s, ~9 
One aspect of adiponectin research in adolescents which helps shed light on the 
relationship between adiposity and adiponectin level is the area of weight loss. Research in 
adiponectin and weight loss has uncovered that a decrease in weight significantly increases 
adiponectin concentrations in adolescents. 34, 39 Similar findings have been seen with adult 
weight loss.4o
Physical activity and adiponectin (adults) 
Few studies have examined the relationship between physical activity and 
adiponectin in adults and no studies have investigated this topic in adolescents. Monzillo et 
al. 41 used physical activity in the form of an exercise program incorporated into a lifestyle 
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adjustment and found an increase in adiponectin levels after the 6 month intervention. 
However the increase in adiponectin more than likely came from a decrease in adipose 
tissue.41 A second group investigated the effects of intense intermittent exercise on 
adiponectin levels, there were no significant differences identified between control and 
exercise groups.42 More research is needed to determine if physical activities plays a role in 
the control of plasma adiponectin concentrations. 
Summary and Conclusions 
Obesity and its link to the metabolic syndrome and atherosclerotic complications 
currently affect developed countries around the world. The metabolic syndrome and 
atherosclerosis are serious conditions that may lead to death if left untreated.l s In order to 
address these problems more information is needed to formulate preventative measures. One 
avenue of investigation that may reveal more information about the control of obesity is the 
secratory role of adipose tissue. Adiponectin is one of the primary adipocytokines of interest 
due to its anti-atherogenic, anti-inflammatory, and insulin sensitizing effects.lo, 21, 29 
Numerous questions have been answered regarding adiponectin including the relationships 
with adiposity, gender, age, and metabolic/atherogenic interactions. 10'19' 29, 34 Research has 
thus far neglected to address the area of physical activity and adiponectin in an adolescent 
population. Physical activity could play a strong role in the concentrations of adiponectin 
released in the body. The discovery of a connection between adiponectin and physical 
activity would lead to a greater understanding of how to address the negative consequences 
associated with adolescent obesity. 
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CHAPTER 3: PHYSICAL ACTIVITY, FATNESS, AND ADIPONECTIN IN YOUNG 
MALE5 (MANUSCRIPT) 
Introduction 
Obesity is increasing by alarming proportions in developed countries and is now 
considered a global epidemic.l To better understand the etiology and consequences of 
obesity and to develop effective treatment strategies, an emerging research area involves the 
secretory role of the adipocyte. Traditionally considered a storage depot for triglycerides, the 
hormonal function of adipose tissue appears to play a significant role in inflammatory 
homeostasis through the release of cytokines (e.g., adipokines or adipocytokines). 2
Adiponectin is an adipocyte-released cytokine identified as having a mediating role in 
obesity and its co-morbidities. Adiponectin has anti-inflammatory and anti-atherogenic 
properties and has been linked to insulin resistance. 3-5 Recent research indicates that the 
administration of adiponectin to insulin resistant mice increases free fatty acid utilization, 
lowers plasma glucose levels, and hinders the development of atherosclerotic plaque. 
6_g 
Several studies have shown an inverse association between measures of adiposity 
(e.g., body mass index (BMI), fat mass, etc.) and adiponectin. 9-13 Hence, given the 
association between obesity, inflammation, atherosclerosis, and insulin resistance, other 
research has examined the effects of weight loss on adiponectin in obese subjects. The 
findings from these studies indicate that adiponectin concentrations increase following 
weight loss in conjunction with diet and exercise intervention. 14-16 For example Reinehr et 
al. 14 showed a 22% increase in adiponectin following a 3.1 kg decrease in body weight and 
5% decrease in %body fat among 6-14 year old obese children involved in a weight loss 
intervention. However, it is yet to be determined if exercise plays an independent role from 
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adiposity in circulating serum adiponectin levels. The majority of exercise-related research, 
whether acute or training interventions, has failed to identify an increase in adiponectin 
concentrations. ' ~-21 To date, only one study has reported an increase in adiponectin 
following multiple bouts of low -to -moderate intensity exercise. 22 Although previous 
research has examined the effects of exercise training on adiponectin, no study has examined 
free-living daily physical activity. Training sessions are usually high intensity, short duration, 
and do not account for physical activity outside the training bout. On the other hand, 
measurement of free- living daily physical activity provides a representation of total 
accumulated physical activity, rather than a specific training bout. Therefore, the purpose of 
this study was to identify an independent relationship between physical activity and 
adiponectin in young men. The approach used in this study was to examine differences in 
adiponectin between three distinct groups —distance runners, normal weight and overweight 
subjects, and also to identify correlations between objectively-measured, free-living physical 
activity and adiponectin. 
Methods 
Participants: Thirty-eight young males, 12-21 years of age, participated in the study. 
Subjects were recruited by advertisement and word-of -mouth. Five participants were 
excluded due to incomplete physical activity and/or maximal treadmill data. Participants 
were divided into three groups: distance runners, normal weight, and overweight. The latter 
two groups were based on the BMI. Overweight participants possessed a BMI equal to or 
greater than the age appropriate reference value according to Cole et al. 2~ This study was 
approved by the university human subjects review board. Informed consent and assent forms 
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(when applicable) were signed by parents and child, respectively. 
Anthropometry: Standing height was measured to the nearest O.lcm with a wall mounted 
stadiometer (Harpenden, London, UK). During the standing height measurement participants 
removed shoes, stood with feet together, and had arms relaxed at their sides. For standing 
height measurements the head was in the Frankfort plane, participants were instructed to 
inhale while the measurement was taken. Body mass was measured with participants in a t- 
shirt and shorts on an electronic scale (Seca 770) to the nearest 0.1 kg. The BMI was 
calculated as weight (kg)/height (m2). To provide an indicator of visceral or abdominal 
adiposity, waist circumference (WC) was measured to the nearest 0.1 cm with a Gullick tape 
at the superior border of the iliac crest. A bio-electrical impedance analyzer (RJL 101, 
Clinton, MI) was used to assess body composition according to manufactures procedures. 
Fat free mass was calculated using the equations of Goran et al. 24 Fat mass and percent fat 
were obtained through calculations (fat Mass =body mass-fat free mass, %fat= (fat mass/ 
body mass) * 10 ). 
Assessment of Peak Oxygen Consumption (Peak Vo2): Peak Vol was determined during a 
graded maximal exercise test to exhaustion. The treadmill protocol consisted of 3-minute 
stages of increasing speed and grade until volitional exhaustion or test termination. Expired 
respiratory gases were collected and continually sampled via indirect calriometry (Cosmed 
Quark b2, Rome, Italy) for the measurement of oxygen consumption (Vo2), carbon dioxide 
production (VCo2), and minute ventilation. Peak Vol was expressed relative to body mass 
(rril/kg/min). 
Habitual Physical Activity: Habitual free-living physical activity was assessed with the 
Manufacturing Technology Inc. (MTI) uniaxial accelerometer (Shalimar, FL). The MTI is a 
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small (Sx4x1.5 cm), lightweight (43 g) unit that produces values that are represented as total 
activity counts. The activity monitor was worn on the right hip for four days with at least one 
weekend day. Days were excluded if the unit was worn less than 8 hours and/or multiple 
undocumented large gaps of zero counts were present in the data. Summing the 24, 60- 
minute time blocks comprising each day generated daily total activity counts which were 
converted to counts/min based on the total daily time the unit was worn. Time spent in 
moderate physical activity (3-5.9 METS) (MPA) and vigorous physical activity (>6 METS) 
(VPA) were determined based on age-specific cut-points. 25
Blood Measurements: Participants arrived at the laboratory following a 12 hour over-night 
fast. Immediately following bio-electrical impedance a blood draw occurred via an 
antecubital venipuncture performed by a trained phlebotomist. Immediately following 
phlebotomy, blood samples were centrifuged at 4,000 rpm at 4° C and stored at -80° C until 
assayed. Adiponectin was measured using an enzyme-linked immunosorbent assay 
(ELISA)(R&D Systems, Minneapolis Minnesota) following manufactures instructions. 
Duplicate sampling was used to determine intra-assay variability. Intra-assay coefficient of 
variation was 9.04%. 
Statistical Analysis: Descriptive statistics and the differences between the three groups were 
initially examined by one-way ANOVA. The inter-relationships among physical activity, 
peak Vol, adiposity measures and adiponectin were initially examined by bivariate 
correlations. To examine the independent aspects of physical activity on adiponectin, 
subsequent analyses were covaried for age and fat mass. Analysis of covariance was used to 
further examine differences in adiponectin between the overweight, normal weight, and 
runners, and partial correlations, controlling for both age and fat mass, were used to further 
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examine the association between physical activity, peak Vol and adiponectin. An alpha level 
of p<0.05 was used in all analyses which were calculated with the SPSS package (SPSS, 
Chic ago, Illinois) . 
Results 
Descriptive characteristics of the total sample and for the subjects grouped by runners, 
normal weight, and overweight are shown in Table 1. The overweight group had significantly 
higher BMI, WC, fat free mass, fat mass, and lower peak Vol compared to the runners and 
normal weight. Age, vigorous physical activity, total physical activity (expressed as counts 
per minute), and peak Vol were significantly higher in the runners compared to the other two 
groups. There were similar values for BMI and body fat measures between the runners and 
the normal weight. Results for ANOVA indicated that adiponectin was significantly greater 
in the runners compared to the overweight and normal groups. The large variation within and 
between the groups should be noted (i.e., range of values). 
Bivariate correlations among the variables are shown in Table 2. Fat mass, WC and 
BMI were all highly correlated (r = 0.953 to r = 0.961). There was also a strong correlation 
between vigorous physical activity (VPA) and peak Vol and (r = 0.709). There was a 
significant correlation between peak Vol and adiponectin (r = 0.33). Likewise, fat mass was 
shown to be moderately inversely related to adiponectin (r = -0.24). There was also a 
moderately strong correlation between peak Vol and fat mass (r = -0.71). 
Given the association between age and fat mass with adiponectin, these variables 
were controlled using ANCOVA to examine the independent contribution of physical 
activity and possibly peak Vol on adiponectin. Using this approach, there was no significant 
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difference in adiponectin between groups (p = 0.22) (Figure 1). However, the difference 
between runners and the other two groups was about 66% (7.43~g v. 4.93µg v. 4.81µg). The 
correlations between VPA and adiponectin was r = 0.252. However, when partial 
correlation was utilized the association between VPA and adiponectin decreased.(r =0.083). 
Based on the inter-relationships between vigorous physical activity, peak Vol, fat 
mass, and adiponectin (Figure 2), partial correlations were used to further investigate 
independent relationships between adiponectin and 1) peak Vol controlling for age and fat 
mass, 2)fat mass controlling for VoZ peak and age. When age and fat mass were controlled, 
the significant relationship between adiponectin and Vol peak (r = 0.11, p= 0.509) was no 
longer significant. Controlling for Vol peak and age, the correlation between fat mass and 
adiponectin was also lowered (r = -0.08, p=0.63). 
Discussion 
In the past 5-10 years, the prevalence of obesity has continued to increase and the 
view of adipocyte physiology has also changed. Adipose tissue has traditionally been 
thought of as just a storage depot for triglycerides. However, it is now known that adipose 
tissue secretes hormonally active substrates (e.g., adipocytokines) that appear to mediate the 
relationship between obesity and features of the metabolic syndrome (e.g. insulin resistance, 
hypertension, atherogenesis). 2 One such adipocytokine -adiponectin —was examined in the 
present study. The findings indicate that adiponectin differs between highly physically 
active/lean distance runners and normal weight and overweight young males. The observed 
differences in adiponectin between groups may suggest that several factors including 
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oxidative capacity, muscle-fat bi-directional communication, and vigorous physical acitivity 
may contribute to an up-regulation of adiponectin production. 
The inverse correlations between measures of adiposity and adiponectin found here 
are consistent with previous research. 14, 1 s, 26-2g In general, correlations between measures of 
adiposity (% body fat, BMI, FM) and adiponectin range between -0.22 to -0.43. In the 
present study, correlations were at the lower end of this spectrum (r = -0.24 to -0.290). The 
lower correlations in this study compared to previous research may be due to a relatively lean 
population as previous research has focused mainly on obese individuals. i2, i3, 29 Given that 
the level of adiposity is a correlate of adiponectin concentrations, recent investigations have 
focused on the effects of weight loss through exercise, diet, or surgical interventions on 
adiponectin. The results of these studies demonstrate an increase in adiponectin 
concentrations with weight reduction. 14 2g However, it remains to be determined if there is 
an independent effect of exercise on adiponectin. 14 To date, the limited research has focused 
on the effects of acute exercise, specifically high-intensity intermittent exercise sessions. 21
Kramer et al. 21 failed to show an increase in adiponectin concentration with a 30 minute bout 
of high intensity running. The effects of long-term exercise training on adiponectin have also 
been investigated, and in general, indicate no change in plasma adiponectin levels. 1~-Zo 
Kriketos et al. 22 is the only study to show an increase (260°Io) in adiponectin levels 
following ~ 1 week, of 40 minutes of moderate intensity aerobic exercise performed on at 
least 2 days. In the present study, adiponectin was compared in three distinct groups of males. 
Highly-trained long distance runners, a normal weight group and an overweight group with 
the long distance runners serving as a special exposure group since they accumulate a large 
amount of total and vigorous intensity physical activity that is rarely seen in the general 
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population. When adiponectin concentration was compared between groups, the runners had 
significantly higher adiponectin levels (p = 0.027). After covary for fat mass the runners 
retained a higher level of adiponectin (~66%) compared to the other groups, although the 
effect did not meet statistical significance. It is important to note that the normal weight and 
runners had similar body compositions but differing adiponectin concentrations, indicating 
fat mass does not explain much of the variance between these two groups. Previous research 
has only examined exercise training protocols and thus has failed to recognize the importance 
of habitual free-living physical activity on adiponectin. In the present study, habitual free- 
living physical activity was measured with an objective measurement tool (MTI 
accelerometer). Although the results failed to identify a significant correlation between 
physical activity and adiponectin, it remains possible that vigorous physical activity (as 
opposed to total physical activity) may act indirectly through its influence on peak Vol
and/or fat mass (see Figure 2). 
Given the inter-relationships between several key variables, a subsequent analysis 
was undertaken to further explore the complex relationships between peak Vol, fat mass and 
adiponectin. Peak Vol is accepted as an indicator of the oxidative capacity of skeletal muscle. 
3o Although research has not examined the relationship between oxidative capacity of muscle 
and cytokine release from this tissue, it is possible a relationship exists due to the research 
indicating an altered IL-6 concentration in special populations. Therefore, it was of interest 
to further examine the potential role of peak Vol and adiponectin. Although the relationship 
between peak Vol and adiponectin was significant (r = 0.33) (Figure2) the statistical 
significance was not retained when fat mass was controlled in partial correlation. Likewise, 
statistical significance was not attained when the relationship between fat mass and 
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adiponectin was investigated controlling for Vol. Overall, the results indicate that both fat 
mass and peak Vol are equally important in influencing adiponectin concentrations. 
Even though the oxidative capacity of muscle may not have a direct role in the 
regulation of cytokines, muscle tissue does have an active role in inflammatory homeostasis. 
31, 32 Furthermore, several authors have suggested the importance of a muscle-fat cross-talk 
relationship with adiponectin. Bi-directional communication between muscle and fat 
suggests that muscle derived cytokines mediate effects on adipose mass and adipokine 
production.31-33 It is possible that cytokines derived from muscle may regulate adiponectin 
and the inflammatory response of adipose tissue, thereby playing a key role in the metabolic 
syndrome and obesity. Further examination into adipose and muscle cytokine signaling may 
reveal a possible treatment to target cytokine induced metabolic dysregulation. 
The mild inflammatory state seen in obesity has been implicated as a mediator of 
metabolic disruption (ie. insulin resistance}. 34 Research demonstrates that substrate 
utilization and metabolic function are down-regulated by interactions with inflammatory 
cytokines. Two of the main cytokines that can influence insulin resistance and fuel utilization 
are TNF-a and IL-6.34' 3s Acute exercise has been shown to result in an increase in IL-6. It is 
unknown if IL-6 released during exercise affects fuel sparing or aids in releasing available 
fuel sources for use in working tissues. Bi-directional communication between muscle and 
fat that occurs during and after exercise may influence fuel utilization and potentially result 
in an anti-inflammatory response, which would ultimately affect obesity. Cytokines thought 
to be involved in bi-directional communication include IL-6, IL-15, and adiponectin. 
Research indicates that muscle tissue can secrete IL-6, which is an important cytokine 
related to inflammation. 36 There are currently two view points regarding the role of IL-6, 
28 
one considers IL-6 to be anti-inflammatory while the other attributes inflammatory properties 
to the cytokine. In vitro research has identified an inhibition of adiponectin in the presence 
of IL-6. 37 In vitro down regulation of adiponectin identifies IL-6 as an inflammatory 
cytokine. However, the effects of IL-6 on adiponectin in vivo are inconclusive. 3s As an anti-
inflammatory cytokine IL-6 has been identified as inhibiting the release of one inflammatory 
cytokine, TNF-alpha. 39-4 It is speculated that TNF-alpha plays a role in the inhibition of 
adiponectin production and release. 3s, 4s Therefore, it may be hypothesized that a brief 
increase in IL-6 may initiate an anti-inflammatory response. Research suggests IL-6 can 
stimulate production of the two anti-inflammatory cytokines IL-10 and IL- lra. 46A brief 
induction of anti-inflammatory processes whether by IL-6 directly or through down stream 
signaling may suppress the effects of the mild inflammatory state associated with obesity. In 
respect to the current study, it may be possible that a short term increase in IL-6 during 
physical activity is restricting TNF-a production, thus alleviating the inhibition of 
adiponectin. 
Due to the large production of IL-6 by muscle tissue, research has focused on the 
role exercise plays on IL-6 concentration. IL-6 concentrations have been shown to increase 
following acute bouts of exercise and the exercise intensity is positively related to IL-6 
concentrations. 47' 4s Given that runners exercise at high intensities for longer duration, it is 
expected that the total amount of IL-6 released by muscle during the exercise session would 
be greater than in the normal population (although at rest serum levels of IL-6 are lower in 
runners). Current research suggests the main functions of IL-6 during exercise are to aid in 
fuel mobilization through lipolysis of adipose tissue and improvement of glucose uptake. 49 
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The combined metabolic effects of increased glucose uptake and lipolysis seen with 
increased IL-6 are advantages to working tissue during exercise. 
Contrary to acute exercise, the concentration of IL-6 either decreases or remains 
stable with chronic training. so, 51, 52Research has shown that 12 weeks of aerobic training in 
young adults failed to elicit a change in IL-6. so, s 1 while participation in aerobic training was 
shown to lower IL-6 in elderly individuals that commonly experience exaggerated baseline 
inflammatory levels. 52 The current research in aerobic training and IL-6 is supportive of the 
long standing belief that exercise can decrease the risk of cardiovascular disease. 
The second cytokine involved in the muscle-fat cross-talk model is IL-15. IL-15 is a 
relatively new cytokine to be considered in the metabolic syndrome milieu. Research 
indicates that IL-15 may increase adiponectin concentrations and have greater lipolytic 
activity than IL-6. 32, s3 IL-15 is secreted from muscle fibers and adipose tissue.54 The factor 
responsible for triggering IL-15 release from skeletal muscle is still unknown. However, it 
can be speculated that IL-15 concentration may be up-regulated as a result of physical 
activity/ muscle contraction. The high lipolytic effects attributed to IL-15 would be beneficial 
in maintaining energy release for use in working tissue. However, research has not identified 
a pathway in which muscle contraction would result in IL-15 release; thus it is unclear if 
physical activity results in greater IL-15 concentrations. Regardless, greater IL-15 
concentrations could theoretically explain the higher adiponectin concentration in runners 
compared to the normal weight group, despite similar body composition. 
The role of physical activity on the regulation of immune function is a complicated 
issue. As mentioned previously, tissue specific inflammation results in a down regulation of 
metabolic function. Metabolic dysregulation may lead to lowering of anti-inflammatory 
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cytokine production. Recall that the runners had greater peak Vol than the normal weight or 
overweight groups. It can be inferred from peak Vol that the oxidative capacity of the 
runner's muscle is greater. When oxidative capacity increases the metabolic machinery in 
that individual becomes more energy efficient. Specifically, there is a shift to a greater 
reliance on FFA for fuel.ss Since the metabolic machinery in the muscle shift to a reliance on 
more FFA there would need to be an increase in lipolysis to provide adequate FFA for fuel. 
The increase in lipolysis may occur through communication from lipolysic cytokines 
originating from muscle (IL-6 and IL-15). 49, s3 If IL-6 and IL-15 are increasing to aid in 
lipolysis, their presence may initiate anti-inflammatory processes. The peak vo2, adiponectin, 
muscle-fat cross-talk research reiterates the fact that multiple factors are involved in the 
regulation of adiponectin. 
When peak Vol, fat mass and vigorous physical activity were used in multiple linear 
regression, they combined to explain 11 % of the variance of serum adiponectin 
concentrations (data not shown). Taking this into account it appears the combination of 
multiple variables may be responsible for the higher adiponectin in the runners. One variable 
not examined here that may explain a large percent of the unexplained variance is genetics. 
A limited number of studies suggest a strong influence of genetics on adiponectin. In a recent 
study of 805 Hispanic children, Butte et al. s6 identified that adiponectin is 93% heritable in 
this population. Among 1100 adults with northern Europe ancestry, Comuzzie et al. s~ found 
an estimated heritability of 46%. Taken together, serum adiponectin is a complex, multi-
factorial phenotype influenced by genes, the environment, and possibly gene-environment 
interactions. 
31 
One limitation to the present study was the use of BMI to separate the normal and 
overweight groups. It is widely known that BMI fails to account for FFM. 58 Three subjects 
in the overweight group had a %body fat less than 10%, which indicates greater lean mass 
for height. Since BMI is widely used in clinical medicine, it was chosen to separate the 
normal weight and overweight groups. Another limitation that possibly explains the reason 
why adiposity and adiponectin were weakly correlated in this study may be the use of 
bioelectrical impendence. B ioelectrical impendence is dependent on hydration, and if 
participants were not at optimal hydration room for error would increase. Several studies 
have bypassed bioelectrical impedance by utilizing dual x-ray absorbtiometry to determine 
adiposity. 29, 51, 59 
In summary, the results of this study show an increased fasting plasma adiponectin in 
individuals that accumulate large amounts of vigorous physical activity accompanied by high 
peak Vol and low fat mass. These findings highlight the complex relationship between 
vigorous physical activity, fat mass, Vol peak and adiponectin. Further research is warranted 
to identify the specific roles these variables play in the elevation of adiponectin 
concentrations. 
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Tables and Figures 
Table 1. Descriptive characteristics of the sample. Values represent mean (SE) and 
range. 
Runners Normal weight Overweight Total 
(n=12) (n=10) (n=11) (n=33) 
Age (yr) 19.9 (0.3) ab 16.8 (1.1) 16.2 (0.7) 17.5 (0.5) 
18.5-21.7 12.6-22.6 12.1-19 12.1-22.6 
Ht (cm) 177.8 (1.8) 175.9 (3.0) 170.5 (2.6) 175.1(1.4) 
163.7-186.6 161.1-188.5 155.4-183.0 155.4-188.5 
Wt (kg) 63.9 (1.9) 64.9 (3.9) 91.0 (7.8) 74.2 (3.6) 
55.3-79.6 42.5-80.5 53.9-137.3 42.5-137.5 
BMI (kg/m2) 20.2 (0.4) b 21.0 (1.1) `  31.1 (2.5) 24.3 (1.2) 
18.7-22.9 15.9-27.1 22.3-47.1 15.9-47.1 
WC (cm) 73.9 (1.0) b 76.2 (2.7) `  100.5 (6.6) 84.4 (3.2) 
69.8-82.0 62.5-87.3 72.3-144.3 62.3-144.3 
FFM (kg) 55.4 (1.5) b 57.2 (3.2) `  64.5 (3.3) 59.2 (1.7) 
48.7-68.7 40.7-74.5 44.0-82.9 40.7-82.9 
FM (kg) 8.5 (0.7) b 7.7 (1.6) `  26.6 (5.1) 14.7 (2.3) 
4.2-10.9 1.7-15.5 8.8-60.1 1.7-60.1 
BF% 13.2 (1.0) b 11.4 (2.2) ~ 26.9 (2.9) 17.6 (1.7) 
7.3-17.2 3.1-21.1 14.3-46.0 3.1-46.0 
Vigorous PA (min/d) 51.1 (5.2) ab 16.2 (6.2) 11.2 (4.7) 25.7 (4.4) 
24.0-86.0 0-62.0 0-47.0 0-86.0 
PA (cnts/min) 1074 (119.4) 664.5 (139.1) 514.4 (69.1) 746.6 (75.5) 
700.6-2169.2 325.8-1837.1 254.7-863.2 208.7-2169.2 
Vol Peak (mVkg/min) 71.9 (1.2) ab 53.5 (2.7) ~ 39.5 (3.8) 54.8 (2.8) 
66.9-80.6 35.5-67.9 21.7-62.7 21.7-80.6 
Adiponectin (µg) 7.6 (1.0) ab 5.0 (0.8) 4.4 (0.5) 5.8 (0.5) 
2.6-14.8 2.5-10.5 1.7-8.0 2.7-14.8 
a significant difference between runners and normal weight,b runners and overweight, 
normal weight and overweight; Ht, height; Wt, weight; BMI, body mass index; WC, waist 
circumference; FFM, fat free mass; FM, fat mass; BF%, %body fat; PA, physical activity 
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Table 2. Inter-relationships among age, adiposity, physical activity, peak Vol and 
adiponectin. 
Vol PA 
Age WC BMI FM Peak VPA cts/min Adiponectin 
Age - -0.079 -0.088 -0.015 0.475* 0.486* 0.504* 0.247 
WC - 0.953 * 0.961 * 0.743* -0.427* -0.36* -0.290 
BMI - 0.955 * 0.696* -0.413 * 0.365 * -0.289 
FM - 0.707* -0.364* -0.35* -0.244 
Peak Vol - 0.709* 0.583* 0.332* 
VPA - 0.823 * 0.252 
PA cts/min - 0.062 
Adiponectin 
Values represent bivariate Pearson correlation coefficients. 
*p<0.05 
Table 3. Partial correlations, controlling for age and fat mass, between physical activity, 
peak Vol and adiponectin. 
Vigorous PA 
PA cnts/min 
Peak Vol
Adiponectin 
0.083 
-0.166 
0.108 
Figure 1. Differences in adiponectin between runners, normal weight and overweight 
males. Values acre age and fat mass adjusted mean (SE) 
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Figure 2. Inter-relationships among vigorous physical activity, peak Vol, and fat mass, 
and adiponectin among young males, 12-21 yrs. 
Vigorous PA 
0.62 
Adiponectin 
-0.43 
Pear / , 0.33 -0.24 
Vol -0.79 
Fat 
Mass 
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CHAPTER 4: GENERAL CONCLUSIONS 
The metabolic syndrome and atherosclerotic complications are frequently seen in 
obese individuals in developed countries around the world. l It is now known that the 
secretory function of adipose tissue plays a role in inflammatory homeostasis. Adiponectin is 
responsible for anti-atherogenic, anti-inflammatory, and insulin sensitizing effects.2, 3, 4 The 
relationships adiponectin has with adiposity, gender, age, and metabolic/atherogenic 
interactions have been previously investigated. 2' 3, 4, s, 6 Physical activity has received little 
attention with regards to adiponectin. The results from this thesis identify an increase in 
fasting plasma adiponectin in young males that accumulate large amounts of vigorous 
physical activity and exhibit a high peak Vol and low fat mass. This thesis highlighted the 
various factors that effect adiponectin concentration. It is evident that the relationships 
between vigorous physical activity, fat mass, Vol peak, muscle-fat bi-directional 
communcation and adiponectin are complex, and justify further research. 
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